Cellectar Biosciences, Inc.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of proprietary cancer therapies. The company leverages its unique Phospholipid Drug Conjugate (PDC)™ delivery platform, which is designed to selectively target cancer cells by exploiting lipid rafts in plasma membranes, allowing for the delivery of therapeutic agents such as radioisotopes and small molecule cytotoxins with improved efficacy and reduced off-target effects. The company's pipeline is centered on its lead candidate, iopofosine I 131, a first-in-class PDC currently under investigation for hematologic malignancies including relapsed or refractory Waldenström macroglobulinemia (WM). Cellectar is actively pursuing regulatory pathways for accelerated approval in the U.S. and conditional marketing authorization in Europe, while simultaneously advancing earlier-stage programs like CLR 125 for solid tumors.